Novartis Investigative Site
A Coruña 15009
4 studies enrolling now · 31 studies all time
What they study most
ALK Positive Malignancies, Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease (ASCVD), Autoimmunity, Inflammation, Breast Cancer, Carcinoma, Renal Cell, Cardiovascular Disease and Lipoprotein(a), Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD), Coronary Artery Disease, Early Breast Cancer, Heterozygous or Homozygous Familial Hypercholesterolemia
Studies at this site
- Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD — Recruiting now
- An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) — Recruiting now
- A Study of 177Lu-FAP-2286 in Advanced Solid Tumors — Recruiting now
- Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. — Recruiting now
- Secukinumab Open Label Roll-over Extension Protocol — Recruiting now
- EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS) — Recruiting now
- Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies — Recruiting now
- A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
- Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) — Running, not enrolling
- Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
- Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events — Running, not enrolling
- A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. — Running, not enrolling
- Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome — Completed
- Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) — Completed
- Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study — Running, not enrolling
- Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease — Running, not enrolling
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
- Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
- Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis — Stopped early
- A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer — Running, not enrolling
- A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA — Stopped early
- Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis — Completed
- Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy — Stopped early
- Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer — Completed
- A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer — Completed
- Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
- Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma — Completed
- Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer — Completed
- Imatinib (QTI571) in Pulmonary Arterial Hypertension — Completed
- Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD) — Completed
- Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD) — Completed